AzTrials
AzTrials

Heart Failure - NYHA II - IVCARDCOPNCT06661161

Calibration of AlgoRithm for Detection of Cardiac Decompensation Via Parametric Objects (CARDCOP)

An observational study of Heart Failure - NYHA II - IV, run by University Hospital, Brest at 3 sites in France.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The goal of the study is to calibrate the algorithmic model of the TakeCoeur AI device to detect early heart failure decompensation in patients with heart failure, using physiological data (clinical) actively and passively collected through connected medical devices (watch, blood pressure monitor, and scale). Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Heart Failure - NYHA II - IV
How many people
640 participants
Where
3 sitesFrance
Study dates
Nov 2024to May 2026
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Participation in the study will be offered to any patient consulting a cardiologist/cardio-geriatrician at one of the participating centers who meets the inclusion criteria and non inclusion criteria.

Who may be able to join

  • Age ≥ 18 years
  • Patient diagnosed with chronic heart failure, confirmed by a cardiologist/cardio-geriatrician (regardless of the type and etiology of the disease), meeting at least one of the following two conditions:
  • Hospitalization in the past 12 months for a heart failure exacerbation.
  • NYHA class II to IV (New York Heart Association) at the time of inclusion, with elevated natriuretic peptide levels (BNP \> 100 pg/mL or NT-proBNP \> 1000 pg/mL).
  • French speaking patient
  • Patient equipped with a smartphone, computer, or tablet with internet/cellular access (of with the help of a caregiver)
  • Patient affiliated with a social security scheme

Who cannot join

  • Patient undergoing dialysis for renal failure
  • Patient who has received or is scheduled to receive a heart transplant or circulatory assistance within the next 12 months
  • Patient with a left ventricular ejection fraction ≥ 50% (for non-diastolic heart failure)
  • Obese patient with a body mass index ≥ 40 kg/m²
  • Patient with severe aortic stenosis who is contraindicated for surgery or TAVI
  • Patient with a life expectancy of \< 1 year due to a condition other than heart failure (cancer, cirrhosis, respiratory failure, etc.)
Show all 11Show fewer
  • Patient already benefiting from a telemonitoring device
  • Physical or psychological inability (dementia, schizophrenia, substance-related disorder) of the patient or caregiver to use the digital data collection device, as judged by the physician
  • Patient refusal to allow the transmission of the data necessary for monitoring the effective use of the device and obtaining individualized or national real-world usage results
  • Patient under guardianship, curatorship, or any other administrative or judicial measure restricting rights and freedoms
  • Patient unable to wear the watch for the duration of the study due to skin conditions

Trial locations and contacts

3 sites in 1 country.

France3 sites
  • Chu Brest

    Brest, 29609

    Jacques MANSOURATI, PR, +33(0)298347405, jacques.mansourati@chu-brest.fr

  • CH Morlaix

    Morlaix, 29600

    Jacques MANSOURATI, PR, +33 (0)298347405, jacques.mansourati@chu-brest.fr

  • CH Vannes

    Vannes, 56000

    Jean-Michel QUEDILLAC, DR, 0297014141 ext. +33, jean-michel.quedillac@ch-bretagne-atlantique.fr

Other trials in France

About this study

Official title: Calibration of AlgoRithm for Detection of Cardiac Decompensation Via Parametric Objects

The goal of the study is to calibrate the algorithmic model of the TakeCoeur AI device to detect early heart failure decompensation in patients with heart failure, using physiological data (clinical) actively and passively collected through connected medical devices (watch, blood pressure monitor, and scale).

Read the detailed description

In France, more than one million people suffer from chronic heart failure (HF) with an average age of 75 years. HF is a major public health issue, leading to 160,000 hospitalizations and 70,000 deaths each year, with an annual hospitalization cost estimated at €1.6 billion. Heart failure remains the third leading cause of cardiovascular mortality, with a 6 to 9 times higher risk of sudden cardiac death in HF patients compared to the general population.

After the age of 80, approximately 25% of heart failure patients die within three months of a decompensation episode, and nearly 40% within a year. Despite significant progress, the therapeutic management of patients remains complex, and hospitalizations are difficult to anticipate. It is even estimated that nearly 400,000 to 700,000 people with HF remain undiagnosed in France. Avoidable hospitalizations contribute to a deterioration in the quality of life for these patients and sometimes result in death.

Heart failure is a condition characterized by gradual worsening. Initially, the patient may be asymptomatic but progressively start to experience several, if not all, of the following symptoms: marked shortness of breath (dyspnea), edema, difficulty breathing when lying down (orthopnea), rapid weight gain, chronic fatigue, heart palpitations, and a drop in blood pressure upon standing. Monitoring the evolution of these symptoms is crucial to identifying the risk of heart failure decompensation and allowing for early and appropriate intervention to avoid hospitalization.

The progression of these symptoms can be tracked through the monitoring of physiological (clinical) variables such as weight, blood pressure, heart rate, and oxygen saturation. These are widely recognized parameters as indicators of health status and are frequently used in heart failure patient monitoring algorithms, as shown by systematic reviews.

Weight is one of the mandatory parameters to be collected according to HAS recommendations. The American Heart Failure Association (HFSA) and the guidelines of the European Society of Cardiology (ESC) also recommend daily weight monitoring. Blood pressure is also among the recommended clinical symptoms to monitor, as it is a precursor sign of heart failure decompensation.

The four warning signals-shortness of breath, rapid weight gain, lower limb edema, and fatigue (EPOF)-must be monitored, especially after the age of 60, to promote early diagnosis and prevent hospitalizations.

Resting and exercise heart rates can predict the risk of cardiovascular disease. A high resting heart rate is associated with an increased risk of coronary heart disease and all-cause mortality and is also considered a predictive factor for decompensation in HF patients. Respiratory rate has been found to be significantly lower in patients with heart failure decompensation. However, physical activity is linked to better cardiovascular health and reduced mortality . Recommended by the American Heart Association (AHA) as one of the "8 Simple Measures for a Healthy Life", physical activity helps promote heart health.

Continuous and real-time collection of all these physiological (clinical) parameters in heart failure patients at risk of decompensation could improve patient follow-up and help predict the risk of acute heart failure decompensation. Indeed, a better understanding of these parameters, their variations, and their correlations would allow for better characterization of heart failure patients and early identification of decompensation.

This study aims to identify predictive factors of heart failure decompensation to develop and train an early detection algorithm that will be used in telemonitoring after the algorithm's calibration. To collect this data stream, heart failure patients will be equipped with three connected devices (watch, scale, blood pressure monitor) linked to the TakeCoeur AI device. The early detection algorithm for heart failure decompensation will be built based on variations in the physiological parameters collected and the occurrence of heart failure decompensation during the study period.

The patient's clinical data will be collected by the cardiologist at inclusion, and the physiological parameters will be passively and actively collected through connected devices. A baseline for each patient will be established at inclusion, reflecting their initial status. Throughout the study, any deviation or variation from this baseline will be detected. In case of a heart failure decompensation, a link between this decompensation and the variations in digitally collected parameters will be established.

The investigators hypothesize that the early detection of heart failure decompensation by the TakeCoeur AI device will align with the actual occurrence of heart failure decompensation, as recorded through healthcare utilization during this study, with good sensitivity and a low rate of false negatives.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Concordance between the detection of heart failure decompensation by the TakeCoeur AI device and the occurrence of heart failure decompensation

    calibrate the algorithmic model of the TakeCoeur IA device for early detection of cardiac decompensation in patients suffering from heart failure.

    Measured: From enrollment to the end of the 6-month follow-up period.

Secondary outcomes (2)
  1. Evaluate the time (in days) to anticipate cardiac decompensation

    time to predict (in days) the risk of cardiac decompensation

    Measured: From enrollment to the end of the 6-month follow-up period.

  2. Evaluate the compliance of patients with heart failure to the Takecoeur IA device and its connected collection accessories

    • Monthly questionnaire (scale 0 to 4 for edema and shortness of breath) completion rate defined by the following formula: (number of completed questionnaires / total number of questionnaires to be completed) x 100

    Measured: From enrollment to the end of the 6-month follow-up period.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Oct 2024
  2. Study startNov 2024 (estimated)
  3. Primary completionNov 2025 (estimated)
  4. Study completionMay 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
640 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06661161
Sponsor's protocol ID
29BRC24.0222 - CARDCOP
Acronym
CARDCOP
Status last verified
Oct 2024
First submitted
30 Sep 2024
Last updated
28 Oct 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: All collected data that underlie results in a publication

Questions about this trial

What is this clinical trial studying?

An observational study of Heart Failure - NYHA II - IV, run by University Hospital, Brest at 3 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 28 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Jacques MANSOURATI (0298347405 ext. +33, jacques.mansourati@chu-brest.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Concordance between the detection of heart failure decompensation by the TakeCoeur AI device and the occurrence of heart failure decompensation (time frame: From enrollment to the end of the 6-month follow-up period.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Oct 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in